Differential gene expression analysis in the overall tislelizumab-treated GEA cohort identified genes highly expressed in TAP ≥ 5%, HA + tumors, including genes with functions in cell cycle regulatory (such as aurora kinase A [AURKA], ubiquitin-conjugating enzyme 2C [UBE2C], CDC20 and MYBL2), DNA repair (such as RAD54L and FANCD2), and hedgehog signaling (such as WNT5A and IHH) pathways, or with functions as cancer antigens (Supplementary Fig. 9). The gene discussed is FANCD2; the disease is cancer.